SOURCE-LINKED STUDY SUMMARY
Safety and Glycemic Efficacy of Perioperative Liraglutide in Cardiac Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Abstract summarizedQuality not appraised
- What was studied
- Abstract-based systematic review and meta-analysis pooled randomized trials of perioperative subcutaneous liraglutide versus placebo or insulin-based usual care in adults undergoing cardiac surgery.
- Who / model studied
- Seven reports from four trials included 446 randomized cardiac-surgery patients; treatment timing and liraglutide doses are not reported in the supplied abstract.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Liraglutide did not significantly change 30-day mortality, overall postoperative complications, cardiac events, hypoglycemia, or postoperative nausea and vomiting.
- Limitations & context
- Only four trials were available, and wide confidence intervals—especially for mortality and nausea/vomiting—leave substantial uncertainty around those null estimates.
Read summary source ↗ · Prepared 9/23/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1097/crd.0000000000001465